tiprankstipranks
Advertisement
Advertisement

EVMN Stock Latest News

Evommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
Company AnnouncementsEvommune’s EVO756 Migraine Trial: What Investors Should Know About This New Phase 2 Study
1d ago
EVMN
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
PremiumCompany Announcements
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
1d ago
EVMN
Septerna price target lowered to $45 from $52 at Guggenheim
PremiumThe Fly
Septerna price target lowered to $45 from $52 at Guggenheim
1d ago
EVMN
SEPN
Evommune price target lowered to $26 from $55 at Morgan Stanley
PremiumThe Fly
Evommune price target lowered to $26 from $55 at Morgan Stanley
2d ago
EVMN
Evommune downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Evommune downgraded to Neutral from Buy at H.C. Wainwright
2d ago
EVMN
Evommune price target lowered to $28 from $53 at Clear Street
PremiumThe FlyEvommune price target lowered to $28 from $53 at Clear Street
3d ago
EVMN
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
Premium
The Fly
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
3d ago
VZ
CRM
Evommune downgraded to Market Perform from Outperform at William Blair
Premium
The Fly
Evommune downgraded to Market Perform from Outperform at William Blair
3d ago
EVMN
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
PremiumCompany Announcements
Evommune Halts EVO756 Urticaria Trial, Pipeline Advances
3d ago
8K
EVMN
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
PremiumThe Fly
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
3d ago
EVMN
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
PremiumThe Fly
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
10d ago
ABBV
APGE
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
PremiumThe Fly
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
10d ago
ABBV
APGE
Evommune Stockholders Reelect Directors and Ratify Auditor
PremiumCompany AnnouncementsEvommune Stockholders Reelect Directors and Ratify Auditor
30d ago
8K
EVMN
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
Premium
Ratings
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
1M ago
EVMN
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
Premium
Ratings
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
2M ago
EVMN
Evommune price target raised to $55 from $54 at Morgan Stanley
PremiumThe Fly
Evommune price target raised to $55 from $54 at Morgan Stanley
2M ago
EVMN
Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts
PremiumRatings
Evommune Earns Buy Rating on Late-Stage Pipeline Progress and Multiple Near-Term Clinical Catalysts
2M ago
EVMN
Evommune reports Q1 EPS (64c), consensus (71c)
PremiumThe Fly
Evommune reports Q1 EPS (64c), consensus (71c)
2M ago
EVMN
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
PremiumCompany Announcements
Evommune Highlights Q1 Results and Advancing Inflammation Pipeline
2M ago
8K
EVMN
Evommune initiated with a Buy at Stifel
PremiumThe FlyEvommune initiated with a Buy at Stifel
2M ago
EVMN
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis
Premium
Company Announcements
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis
2M ago
EVMN
Six new option listings on April 23rd
Premium
The Fly
Six new option listings on April 23rd
2M ago
GRO
ALOY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >